It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Red blood cells mature within the erythroblastic island (EI) niche that consists of specialized macrophages surrounded by differentiating erythroblasts. Here we establish an in vitro system to model the human EI niche using macrophages that are derived from human induced pluripotent stem cells (iPSCs), and are also genetically programmed to an EI-like phenotype by inducible activation of the transcription factor, KLF1. These EI-like macrophages increase the production of mature, enucleated erythroid cells from umbilical cord blood derived CD34+ haematopoietic progenitor cells and iPSCs; this enhanced production is partially retained even when the contact between progenitor cells and macrophages is inhibited, suggesting that KLF1-induced secreted proteins may be involved in this enhancement. Lastly, we find that the addition of three secreted factors, ANGPTL7, IL-33 and SERPINB2, significantly enhances the production of mature enucleated red blood cells. Our study thus contributes to the ultimate goal of replacing blood transfusion with a manufactured product.
In vitro differentiation of red blood cells (RBCs) is a desirable therapy for various disorders. Here the authors develop a culture system using stem cell-derived macrophages to show that inducible expression of a transcription factor, KLF1, enhances RBC production, potentially through the induction of three soluble factors, ANGPTL7, IL33 and SERPINB2.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Cheng-Tao, Yang 2 ; Fidanza Antonella 1 ; Cassetta Luca 3
; Helen, Taylor A 1 ; McCahill, Angela 4 ; Sellink Erica 5 ; von Lindern Marieke 5 ; van den Akker Emile 5 ; Mountford, Joanne C 4
; Pollard, Jeffrey W 3
; Forrester, Lesley M 1
1 University of Edinburgh, MRC Centre for Regenerative Medicine, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
2 University of Edinburgh, MRC Centre for Regenerative Medicine, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); Adaptimmune, Abingdon, UK (GRID:grid.459303.8)
3 University of Edinburgh, Queens Medical Research Institute, MRC Centre for Reproductive Health, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
4 The Jack Copland Centre, Scottish National Blood Transfusion Service, Edinburgh, UK (GRID:grid.476695.f) (ISNI:0000 0004 0495 4557)
5 The Netherlands and Landsteiner Laboratory, Sanquin Research, Department of Hematopoiesis, Amsterdam, The Netherlands (GRID:grid.417732.4) (ISNI:0000 0001 2234 6887)




